αααααβααΎαBMRN β’ NASDAQ
add
Biomarin Pharmaceutical Inc
61.80$
αααααααααα(0.00%)0.00
61.80$
ααΆααα·αα 27 ααααΆ, 4:11:37 PM ααααβααα -5 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·αααΆαααΈααααΆααααΆααααααΆααα
α’αΆαααα·α
αα·αααΈαα»α
61.73$
α
αααααααααααα
61.23$ - 63.15$
α
ααααααα½αααααΆαα
α»αααααα
60.63$ - 94.85$
ααΎαβαα»αβααΈααααΆα
11.78Β αααΈααΆα USD
ααα ααα½αααΌαααααα
1.53Β ααΆα
α’αα»ααΆα P/E
37.17
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
NASDAQ
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(USD) | αααααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 745.74Β ααΆα | 28.28% |
α
αααΆαααααα·ααααα·ααΆα | 443.39Β ααΆα | 4.88% |
α
αααΌααα»ααα | 106.08Β ααΆα | 162.72% |
ααααΆααα
αααααα»ααα | 14.22 | 104.60% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 0.91 | 97.83% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 132.90Β ααΆα | 136.43% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 21.10% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(USD) | αααααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 930.44Β ααΆα | -17.36% |
ααααααααα»α | 6.85Β αααΈααΆα | 1.38% |
ααΆαααα½ααα»αααααΌαααα»α | 1.44Β αααΈααΆα | -22.75% |
ααΌαβααααα»α | 5.41Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 190.58Β ααΆα | β |
ααααααααααΉαααααα
| 2.17 | β |
ααα
ααααααΎαααααα | 4.09% | β |
ααα
ααααααΎααΎααα»α | 4.59% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(USD) | αααααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | 106.08Β ααΆα | 162.72% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 221.48Β ααΆα | 63.28% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -16.16Β ααΆα | 64.72% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -499.12Β ααΆα | -63,240.74% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -296.70Β ααΆα | -425.93% |
ααα αΌαααΆα
αααααΆααααααα | 165.57Β ααΆα | 86.81% |
α’αααΈ
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
ααΆααααααΎαα‘αΎα
ααΈααΆ 1997
ααΆαα·ααΆαααβαααααΆα
αααααβαααααΆα
αα»ααααα·α
3,401